6533b7dcfe1ef96bd1272adc

RESEARCH PRODUCT

Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing’s disease

Carla GiordanoMaria PitroneValentina GuarnottaAlessandro CiresiGiuseppe Pizzolanti

subject

Pituitary glandmedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismpasireotide cushing diseaseSettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyDiabetes mellitusmedicineIn patientbusiness.industryPituitary ACTH hypersecretionRetrospective cohort studyCushing's diseasemedicine.diseasePasireotideSurgerymedicine.anatomical_structurechemistry030220 oncology & carcinogenesisPituitary surgerybusiness

description

Pituitary surgery represents the first-line treatment for most patients with Cushing’s disease (CD). In the case of surgery failure, additional treatment options are required. Pasireotide has shown favourable results in the first-line treatment of patients with CD, who are not candidates for surgery or in the second-line when surgery has failed. The aim of the current study is to compare the effects of surgery and pasireotide treatment in a cohort of patients with CD, and to evaluate the differences in response rate in terms of hormonal and clinical control, and improvement of metabolic complications

yearjournalcountryeditionlanguage
2017-03-17Endocrine
https://doi.org/10.1007/s12020-017-1276-7